A Post-Authorisation Long-Term Retrospective Safety Cohort Study of Arsenic Trioxide in First Line Low- to Intermediate-Risk Acute Promyelocytic Leukaemia (APL) PatientsFirst published 16/07/2020 Last updated 16/04/2024 EU PAS number: EUPAS36320StudyOngoing